Trump's Latest Name For GLP-1s Has Doctors And Patients Raising An Important Concern

Key Points:

• The use of GLP-1 medications has surged in the U.S., with 11% of adults reporting use in 2024, up from 3% previously; these drugs treat Type 2 diabetes, obesity, and related health issues like high blood pressure and heart disease.
• Former President Donald Trump has frequently referred to GLP-1s using stigmatizing terms like "fat shots" or "fat drugs," which medical professionals and users criticize as fatphobic and reductive of the medications' broad health benefits.
• Healthcare experts emphasize that GLP-1s address complex metabolic and chronic conditions beyond weight loss and warn that Trump's language perpetuates harmful stigma and shame toward people with obesity.
• Users of GLP-1s share personal stories highlighting the medications' life-changing effects on conditions such as diabetes, insulin resistance, inflammation, and obesity, stressing that these drugs are not an "easy" fix but part of comprehensive treatment.
• Medical professionals call for better government support and Medicaid coverage for GLP-1s, urging policymakers to focus on expanding access rather than using derogatory language that undermines public understanding and acceptance.